GlycoBiomarker Leading Innovation Co. Ltd.

About GL-i


GL-i was established as an AIST Start-up, an independent entity by the National Institute of Advanced Industrial Science and Technology (AIST) in the expectation of enhancing and expanding the value of its intellectual property worldwide.
We develop novel clinical diagnostic technologies based on the “glycoprotein analysis platforms”, and further, pursue the drug discovery of not limited in diagnostic agents but also medicinal drugs applying the glycoproteomics technologies. GL-i aims to lead glycan-related medical applications in both diagnostics and clinical medicines. In the future, we expect that our technology will be applied in development of preemptive medicine.

Page Top